New Capital Management LP boosted its holdings in shares of Pfizer Inc. (NYSE:PFE) by 150,000.0% during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 3,002 shares of the biopharmaceutical company’s stock after acquiring an additional 3,000 shares during the quarter. New Capital Management LP’s holdings in Pfizer were worth $98,000 at the end of the most recent quarter.
Other institutional investors and hedge funds have also bought and sold shares of the company. Reik & CO. LLC boosted its holdings in Pfizer by 1.4% in the first quarter. Reik & CO. LLC now owns 19,160 shares of the biopharmaceutical company’s stock valued at $625,000 after acquiring an additional 265 shares in the last quarter. Windsor Capital Management LLC boosted its holdings in shares of Pfizer by 1.6% during the 1st quarter. Windsor Capital Management LLC now owns 17,991 shares of the biopharmaceutical company’s stock valued at $587,000 after buying an additional 276 shares in the last quarter. GYL Financial Synergies LLC boosted its holdings in shares of Pfizer by 0.9% during the 1st quarter. GYL Financial Synergies LLC now owns 30,718 shares of the biopharmaceutical company’s stock valued at $1,003,000 after buying an additional 283 shares in the last quarter. Gilbert & Cook Inc. boosted its holdings in shares of Pfizer by 3.0% during the 1st quarter. Gilbert & Cook Inc. now owns 9,794 shares of the biopharmaceutical company’s stock valued at $320,000 after buying an additional 285 shares in the last quarter. Finally, Bridgeworth LLC boosted its holdings in shares of Pfizer by 1.6% during the 1st quarter. Bridgeworth LLC now owns 18,280 shares of the biopharmaceutical company’s stock valued at $597,000 after buying an additional 289 shares in the last quarter. 70.28% of the stock is currently owned by hedge funds and other institutional investors.
In other Pfizer news, SVP Jennifer B. Damico sold 2,181 shares of the business’s stock in a transaction dated Friday, June 5th. The stock was sold at an average price of $36.13, for a total value of $78,799.53. Following the completion of the transaction, the senior vice president now owns 7,542 shares of the company’s stock, valued at approximately $272,492.46. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, EVP Douglas M. Lankler sold 65,000 shares of the business’s stock in a transaction dated Wednesday, April 29th. The stock was sold at an average price of $37.85, for a total value of $2,460,250.00. Following the completion of the transaction, the executive vice president now directly owns 135,375 shares of the company’s stock, valued at approximately $5,123,943.75. The disclosure for this sale can be found here. In the last three months, insiders sold 69,362 shares of company stock valued at $2,622,691. 0.08% of the stock is owned by insiders.
A number of analysts have recently commented on the stock. Cantor Fitzgerald restated a “buy” rating and set a $53.00 target price on shares of Pfizer in a report on Thursday, March 19th. Royal Bank of Canada restated a “buy” rating and set a $44.00 target price on shares of Pfizer in a report on Monday, April 27th. Piper Sandler boosted their target price on shares of Pfizer from $18.50 to $24.00 in a report on Friday, June 26th. Zacks Investment Research lowered Pfizer from a “buy” rating to a “hold” rating and set a $40.00 price target for the company. in a research report on Monday, May 4th. Finally, TheStreet raised Pfizer from a “c+” rating to a “b” rating in a research report on Monday, June 1st. Ten research analysts have rated the stock with a hold rating and four have given a buy rating to the company. The stock currently has a consensus rating of “Hold” and an average target price of $38.72.
Shares of PFE traded down $0.34 during trading hours on Wednesday, hitting $33.69. The company had a trading volume of 12,890,956 shares, compared to its average volume of 33,425,040. Pfizer Inc. has a 52-week low of $27.88 and a 52-week high of $44.10. The firm has a fifty day moving average price of $35.11 and a 200-day moving average price of $36.13. The company has a debt-to-equity ratio of 0.56, a quick ratio of 0.78 and a current ratio of 1.02. The stock has a market capitalization of $189.03 billion, a price-to-earnings ratio of 12.01, a P/E/G ratio of 2.70 and a beta of 0.68.
Pfizer (NYSE:PFE) last issued its earnings results on Tuesday, April 28th. The biopharmaceutical company reported $0.80 earnings per share for the quarter, topping the Zacks’ consensus estimate of $0.71 by $0.09. Pfizer had a return on equity of 25.76% and a net margin of 31.17%. The business had revenue of $12.03 billion during the quarter, compared to analyst estimates of $11.38 billion. During the same quarter in the previous year, the firm earned $0.85 EPS. Pfizer’s revenue was down 8.3% on a year-over-year basis. Research analysts anticipate that Pfizer Inc. will post 2.88 earnings per share for the current fiscal year.
The firm also recently announced a quarterly dividend, which will be paid on Tuesday, September 1st. Shareholders of record on Friday, July 31st will be given a $0.38 dividend. This represents a $1.52 dividend on an annualized basis and a yield of 4.51%. The ex-dividend date is Thursday, July 30th. Pfizer’s dividend payout ratio (DPR) is 51.53%.
Pfizer Company Profile
Pfizer Inc discovers, develops, manufactures, and sells healthcare products worldwide. It offers medicines and vaccines in various therapeutic areas, including internal medicine, vaccines, oncology, inflammation and immunology, and rare diseases under the Lyrica, Chantix/Champix, Eliquis, Ibrance, Sutent, Xalkori, Inlyta, Xtandi, Enbrel, Xeljanz, Eucrisa, BeneFix, Genotropin, and Refacto AF/Xyntha brands.
Featured Article: Why is total return important?
Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFE).
Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.